SCHEMBL7652532

SCHEMBL7652532

CS(=O)(=O)NC(=O)c1c(OCc2ccccc2)c2ccccc2n1Cc1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.47
HDAC6 Q9UBN7 6/20 0.46
HDAC1 Q13547 5/20 0.46
LMNA P02545 2/20 0.43
CCR2 P41597 2/20 0.42
SCN9A Q15858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAPT P10636 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
POLB P06746 1/20 0.41
HDAC8 Q9BY41 2/20 0.41
SCN7A Q01118 2/20 0.40
HDAC11 Q96DB2 1/20 0.40
BCL2L1 Q07817 1/20 0.40
MCL1 Q07820 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7610043 0.84 CCR2 (0.55) HDAC6HDAC1LMNACCR2SMN1; SMN2
SCHEMBL451443 0.83 SENP5 (0.44) PPARGHDAC6HDAC1LMNASMN1; SMN2
SCHEMBL7606189 0.81 HDAC6 (0.52) HDAC6HDAC1LMNAMAPTL3MBTL1
SCHEMBL7609787 0.79 HDAC1 (0.53) PPARGHDAC6HDAC1LMNASMN1; SMN2
SCHEMBL7606181 0.79 LRRK2 (0.55) HDAC6HDAC1MEN1KMT2APOLB
SCHEMBL7606069 0.74 HDAC6 (0.53) HDAC6HDAC1POLBHDAC8
SCHEMBL7612625 0.72 SGMS2 (0.50) HDAC6HDAC1LMNASMN1; SMN2MAPT
SCHEMBL15625856 0.72 MCL1 (0.74) MCL1
SCHEMBL7611336 0.71 LRRK2 (0.55) HDAC6HDAC1MEN1KMT2APOLB
SCHEMBL7613284 0.70 MAPT (0.53) LMNASMN1; SMN2MAPTL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020068756-A1 PDE IV inhibiting amides, compositions and methods of treatment MERCK FROSST CANADA LTD. (CA) 2002-06-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068756-A1 PDE IV inhibiting amides, compositions and methods of treatment PDE3A, PDE3B, PDE4A PPARG 473/4885HDAC6 59/4885HDAC1 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.